Covert COVID-19 complications: Continuing the use of evidence-based drugs to minimize potentially lethal indirect effects of the pandemic in stroke patients

J Neurol Sci. 2020 Jul 15:414:116883. doi: 10.1016/j.jns.2020.116883. Epub 2020 May 6.

Authors

Meng Lee¹, Chi-Hsin Sally Chen², Bruce Ovbiagele³

Affiliations

¹ Department of Neurology, Chang Gung University College of Medicine, Chang Gung Memorial Hospital, Chiayi Branch, Puzi, Taiwan.
² College of Public Health, National Taiwan University, Taipei, Taiwan.
³ Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Bruce.Ovbiagele@va.gov.

No abstract available

Keywords: COVID-19; Medication discontinuation; Stroke.

Publication types

Letter

MeSH terms

Anticoagulants / supply & distribution
Anticoagulants / therapeutic use
Atrial Fibrillation / complications
Atrial Fibrillation / drug therapy
Betacoronavirus*
COVID-19
Cardiovascular Agents / supply & distribution
Cardiovascular Agents / therapeutic use*
Coronavirus Infections* / complications
Delivery of Health Care*
Drug Monitoring
Evidence-Based Pharmacy Practice* / methods
Evidence-Based Pharmacy Practice* / organization & administration
Humans
Medication Adherence
Medication Systems / organization & administration
Pandemics*
Pneumonia, Viral* / complications
Quarantine
Recurrence
SARS-CoV-2
Secondary Prevention
Stroke / complications
Stroke / drug therapy*
Stroke / mortality

Substances

Anticoagulants
Cardiovascular Agents